Takahashi Hiromasa, Takahashi Masato, Taguchi Kazunori, Sasaki Fumiaki, Todo Satoru
Dept. of Pediatric Surgery, Hokkaido University School of Medicine.
Gan To Kagaku Ryoho. 2003 May;30(5):653-9.
To investigate feasibility and toxicity of weekly paclitaxel administration in the adjuvant therapy of primary breast cancer.
Thirty-one patients with primary breast cancer received sustained weekly infusion of paclitaxel at a dose of 90 mg/body for 6 weeks followed by a 2-week interval. This weekly schedule was repeated twice. Leukocytes were checked immediately before every infusion and the dose was reduced to 80 mg/body when grade 1 neutropenia occurred. All patients were assessable for feasibility and toxicity.
A total 349 weekly paclitaxel infusions were administrated to 31 patients (median, 12 infusions/patient). The median delivered dose-intensity was 88.0 mg/body/week (range 80 to 90). Therapy was well tolerated and completed in 27 patients. Four patients refused to continue the therapy because of nausea, fatigue, dizziness and weight gain. Grade 2 neutropenia occurred in 10 patients (32.3%), but grade 3 neutropenia did not occur. Grade 1 peripheral neuropathy occurred in 3 patients (9.7%). Grade 1 nausea occurred in 3 patients (9.7%).
Weekly paclitaxel administration is well tolerated with a favorable toxicity profile in patients with primary breast cancer in the adjuvant setting. Weekly paclitaxel therapy can be performed safely in the outpatient setting.
探讨每周给予紫杉醇用于原发性乳腺癌辅助治疗的可行性及毒性。
31例原发性乳腺癌患者接受每周持续静脉输注紫杉醇，剂量为90mg/体，共6周，随后间隔2周。此每周给药方案重复两次。每次输注前即刻检查白细胞，当出现1级中性粒细胞减少时，剂量减至80mg/体。所有患者均评估了可行性及毒性。
31例患者共接受349次紫杉醇每周输注（中位数，每位患者12次输注）。中位给药剂量强度为88.0mg/体/周（范围80至90）。27例患者对治疗耐受性良好并完成治疗。4例患者因恶心、疲劳、头晕及体重增加而拒绝继续治疗。10例患者发生2级中性粒细胞减少（32.3%），但未发生3级中性粒细胞减少。3例患者发生1级周围神经病变（9.7%）。3例患者发生1级恶心（9.7%）。
在辅助治疗中，原发性乳腺癌患者对每周给予紫杉醇耐受性良好，毒性反应较轻。每周紫杉醇治疗可在门诊安全进行。
